Cellicon Lab

Cellicon Lab is a bio-venture company specializing in dermal delivery technology of topical-therapeutics. A revolutionary peptide technology, DermiShuttle, enables delivery of cargos to dermis by cell-to-cell transmission and contributes to the development of innovative therapeutics. They have developed 50 novel peptides as an active-compounds, registered about 45 peptides in PCPC and 22 patents.

From the 2021, They developed DermiShuttle that is a proprietary peptide-based technology and it enables delivery of active compounds to dermis by topical-treatment.

N/A

What will we solve?
It can be understood only when it is concluded by ‘Laws of nature’, it is almost impossible for us to take external substance inside through the skin. However, most of skin problems occur in the dermis of the skin. Dermis is the target of topical-therapeutics. However topical-drugs have not been reached to dermis due to SC (stratum corneum) and epidermis as known as a skin barrier.

There have been many approaches to deliver dermis of cargo, but it is believed there is no technology so far. It may be because it does not penetrate only 0.1 mm of SC and epidermis as we know barrier. We started from here. SC and epidermis is not barrier, it is just an object to penetrate for us.

What is the limitation?
There are two different barriers, hydrophobic of SC and hydrophilic of epidermis. Moreover there is no intracelluar space in epidermis.
In order for a drug to be transferred to dermis, it must penetrate a SC and epidermis with which have opposite physicochemical properties. Moreover while SC has intracelluar space, the epidermis has little the space because it consists of living cells known as Keratinocytes. Currently some of technologies can penetrate a part of SC layer, but it is not enough to penetrate the epidermis layer.

CEO Desk:
Min-gyu Soung, PhD, CEO, Founder

After acquiring a Ph.D. in organic chemistry at the University of Tokyo and post doctor in Pacific Northwest Research Institute (Washington, USA). He has focused on researching the development of new peptide drugs for more than 20 years and is focusing on developing peptides that improve problematic skin after the establishment of Cellicon Lab Inc.